8-氨基-3,4-二氢萘-1(2H)-酮 | 624729-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 8-氨基-3,4-二氢萘-1(2H)-酮
• 英文名称: 8-amino-3,4-dihydro-lH-naphthalen-2-one
• 英文别名: 8-ammo-3,4-dihydro-1H-naphthalen-2-one；8-amino-3,4-dihydro-1H-naphthalen-2-one；8-amino-3,4-dihydronaphthalen-2(1H)-one
• CAS: 624729-74-4
• 化学式: C₁₀H₁₁NO
• mdl: MFCD11035884
• 分子量: 161.203
• InChiKey: JPHCRNPKJNUQDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  8-氨基-3,4-二氢萘-1(2H)-酮 在 [RuCl2(benzene)]2 、 (1S,2R)-(-)-1-氨基-2-茚醇 氢氧化钾 作用下， 以 异丙醇 为溶剂， 反应 1.33h， 以56%的产率得到(R)-8-amino-1,2,3,4-tetrahydronaphthalen-2-ol
  参考文献：
  名称：

  [EN] HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES
  [FR] DERIVES HYDROXY-TETRAHYDRO-NAPHTALENYLUREE

  摘要：

  这项发明涉及四氢萘衍生物及其盐，可作为药物配方的有效成分。本发明的四氢萘衍生物作为VR1拮抗剂具有出色的活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗急迫性尿失禁、过度活跃膀胱、慢性疼痛、神经痛、术后疼痛、类风湿关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁、哮喘和慢性阻塞性肺病等炎症性疾病的治疗。

  公开号：

  WO2003095420A1
• 作为产物：
  描述：

  7-乙氧基萘-1-氨基甲酸叔丁酯 在 盐酸 、 水 、 lithium 、 叔丁醇 作用下， 以 1,4-二氧六环 、 四氢呋喃 、 氨 为溶剂， 反应 3.0h， 生成 8-氨基-3,4-二氢萘-1(2H)-酮
  参考文献：
  名称：

  Tetrahydro-naphthols as orally available TRPV1 inhibitors

  摘要：

  Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst maintaining potency. Compound rac-6a is an orally available TRPV1 antagonist with single-digit nanomolar activity. The enantiomers show a low eudismic ratio at the receptor level. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.108

文献信息

• [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDRO-NAPHTHALENE ET D'UREE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005040100A1

  公开（公告）日：2005-05-06

  This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). BHC 03 2 001-Foreign-Countries - 66 - BHC 03 2 001-Foreign-Countries - 65 -

  这项发明涉及四氢萘和脲衍生物及其盐，这些物质可作为药物制剂的活性成分。本发明的四氢萘和脲衍生物具有辣椒素受体（VR1）拮抗活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗与VR1活性相关的泌尿系统疾病或紊乱，如膀胱过度活动（过度活跃膀胱）、尿失禁、神经源性膀胱过度活动（膀胱过度反射）、特发性膀胱过度活动（膀胱不稳定）、良性前列腺增生、下尿路症状；慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风，以及哮喘和慢性阻塞性肺病（COPD）等炎症性疾病。BHC 03 2 001-外国国家 - 66 - BHC 03 2 001-外国国家 - 65 -
• Novel Heterocyclidene Acetamide Derivative
  申请人：Uchida Hideharu

  公开号：US20080287428A1

  公开（公告）日：2008-11-20

  A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like; R 2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X 1 represents O, —NR 3 —, or —S(O)r-; X 2 represents a methylene group, O, —NR 3 —, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

  一个由式(I′)表示的化合物：（其中m、n和p分别表示0到2；q表示0或1；R1表示卤素、烃基、杂环基、烷氧基、烷氧羰基、磺酰胺基、CN基团、NO2基团等；R2表示卤素、氨基、烃基、芳香杂环基或醛基；X1表示O、—NR3—或—S(O)r-；X2表示亚甲基、O、—NR3—或—S(O)r-；Q′表示异芳基基团、异芳基烷基基团、取代芳基基团或芳基烷基基团；Cycle moiety代表芳基环或杂芳基环；波浪线表示E异构体或Z异构体），该化合物的盐，或该化合物或其盐的溶剂络合物。一种药物组合物和一种瞬时受体电位类型I（TRPV1）受体拮抗剂，每种包含至少一种该化合物、该化合物的盐，或该化合物或其盐的溶剂络合物作为活性成分。
• [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES<br/>[FR] TETRAHYDRO-NAPHTALENE ET DERIVES D'UREE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005040119A1

  公开（公告）日：2005-05-06

  This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.

  这项发明涉及一种羟基四氢萘或脲衍生物公式(I)及其盐，它们作为药物制剂的活性成分，其中A代表公式(II)或(III)，其中#代表分子的连接位置，Q1a、Q2a、Q3a和Q4a被定义，E代表公式(IV)或(V)，其中#代表分子的连接位置，Q1b、Q2b、Q3b、Q4b、Q5b、R1b、na、ma、Xa和Ra被定义。
• [EN] TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS<br/>[FR] DERIVES TETRAHYDRO-NAPHTALENE SERVANT D'ANTAGONISTES DU RECEPTEUR VANILLOIDE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004052845A1

  公开（公告）日：2004-06-24

  This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  该发明涉及四氢萘衍生物及其盐，作为药物制剂的活性成分。本发明的四氢萘衍生物作为VR1拮抗剂具有出色的活性，并且适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、急迫性尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和慢性阻塞性肺疾病的治疗。
• [EN] TETRAHYDRO-NAPHTHALENE DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDRO-NAPHTHALENE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004052846A1

  公开（公告）日：2004-06-24

  This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  这项发明涉及四氢萘衍生物及其盐，可用作药物制剂的活性成分。本发明的四氢萘衍生物具有出色的VR1拮抗活性，适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、膀胱过度活跃、急迫性尿失禁、慢性疼痛、神经病痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和慢性阻塞性肺疾病的治疗。